AbbVie EPS - Earnings per Share 2010-2019 | ABBV

AbbVie annual and quarterly earnings per share history from 2010 to 2019. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • AbbVie EPS for the quarter ending September 30, 2019 was $1.26, a 30.39% decline year-over-year.
  • AbbVie EPS for the twelve months ending September 30, 2019 was $2.25, a 53.61% decline year-over-year.
  • AbbVie 2018 annual EPS was $3.66, a 10.91% increase from 2017.
  • AbbVie 2017 annual EPS was $3.3, a 9.09% decline from 2016.
  • AbbVie 2016 annual EPS was $3.63, a 15.97% increase from 2015.
AbbVie Annual EPS
2018 $3.66
2017 $3.30
2016 $3.63
2015 $3.13
2014 $1.10
2013 $2.56
2012 $3.35
2011 $2.18
2010 $2.65
2009 $0.00
AbbVie Quarterly EPS
Q3 2019 $1.26
Q2 2019 $0.49
Q1 2019 $1.65
Q4 2018 $-1.15
Q3 2018 $1.81
Q2 2018 $1.26
Q1 2018 $1.74
Q4 2017 $0.04
Q3 2017 $1.01
Q2 2017 $1.19
Q1 2017 $1.06
Q4 2016 $0.85
Q3 2016 $0.97
Q2 2016 $0.98
Q1 2016 $0.83
Q4 2015 $0.93
Q3 2015 $0.74
Q2 2015 $0.83
Q1 2015 $0.63
Q4 2014 $-0.50
Q3 2014 $0.31
Q2 2014 $0.68
Q1 2014 $0.61
Q4 2013 $0.70
Q3 2013 $0.60
Q2 2013 $0.66
Q1 2013 $0.60
Q4 2012 $0.98
Q3 2012 $1.01
Q2 2012 $0.80
Q1 2012 $0.56
Q4 2011 $0.73
Q3 2011 $0.01
Q2 2011 $0.98
Q1 2011 $0.00
Q4 2010 $0.00
Q4 2009 $0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $127.948B $32.753B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $359.093B 15.56
Roche Holding AG (RHHBY) Switzerland $261.818B 0.00
Merck (MRK) United States $217.580B 16.86
Pfizer (PFE) United States $208.858B 12.41
Novartis AG (NVS) Switzerland $207.477B 17.51
Novo Nordisk (NVO) Denmark $127.967B 22.06
AstraZeneca (AZN) United Kingdom $124.917B 22.56
Sanofi (SNY) France $118.120B 14.51
Eli Lilly (LLY) United States $110.175B 20.35
GlaxoSmithKline (GSK) United Kingdom $109.820B 13.30
Bristol-Myers Squibb (BMY) United States $92.625B 12.95
Bayer (BAYRY) Germany $70.650B 10.46
H Lundbeck (HLUYY) Denmark $7.388B 10.66